Redirected autologous T cells engineered to contain anti-CD19 attached to TCRz and 4-signaling domains
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Redirected autologous T cells engineered to contain anti-CD19 attached to TCRz and 4-signaling domains, covering 2020-10-05 to 2020-10-05. Get the full timeline:
Most recent: Clinical Trial Update: Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas [Phase 2]